Abstract

Research Article

Fifteen year Follow-up of Relapsed/ Refractory Patients with Hodgkin Lymphoma Treated with Autologous Hematopoietic Stem Cell Transplantation

Sabree Abredabo*, Harrah Chiang, Leonard Klein, Tulio Rodriguez and Jacob D Bitran

Published: 02 July, 2024 | Volume 8 - Issue 1 | Pages: 033-037

We reviewed our outcomes of patients with relapsed/refractory Hodgkin Lymphoma treated with autologous stem cell transplant over a 30-year period, 1992 to 2022 and are reporting 15-year Disease-Free Survival (DFS) and Overall Survival (OS) of the 36 patients treated (19 men, 17 women, median age 41). Over the years there were different preparative regimens employed (carmustine, etoposide, melphalan and BCNU, etoposide, cytarabine, and melphalan) as well as post-transplant consolidation therapy (brentuximab). With a median follow-up of 15 years, the DFS is 52% and OS is 64%. Long-term complications include cardiomyopathy and second malignancies.
The use of better salvage regimens and post-transplant consolidation therapy should lead to better outcomes.

Read Full Article HTML DOI: 10.29328/journal.jsctt.1001040 Cite this Article Read Full Article PDF

References

  1. Shanbhag S, Ambinder RF. Hodgkin lymphoma: A review and update on recent progress. CA Cancer J Clin. 2018 Mar;68(2):116-132. doi: 10.3322/caac.21438. Epub 2017 Dec 1. PMID: 29194581; PMCID: PMC5842098.
  2. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995 Dec 7;333(23):1540-5. doi: 10.1056/NEJM199512073332305. PMID: 7477169.
  3. Gunes AK, Dagdas S, Ceran F, Ucar MA, Falay M, Sunu C, Ayli M, Zengin N, Ozet G. Conditioning Regimens for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Stem Cell Transplantation: BEAM Versus High Dose ICE. Indian J Hematol Blood Transfus. 2021 Jan;37(1):82-89. doi: 10.1007/s12288-020-01317-5. Epub 2020 Jul 8. PMID: 33707839; PMCID: PMC7900376.
  4. Randall MP, Spinner MA. Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy. Cancers (Basel). 2023 Sep 11;15(18):4509. doi: 10.3390/cancers15184509. PMID: 37760478; PMCID: PMC10526852.
  5. Moskowitz CH, Walewski J, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Viviani S, Bachanova V, Sureda A, McClendon T, Lee C, Lisano J, Sweetenham J. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018 Dec 20;132(25):2639-2642. doi: 10.1182/blood-2018-07-861641. Epub 2018 Sep 28. PMID: 30266774.
  6. Zulian GB, Selby P, Milan S, Nandi A, Gore M, Forgeson G, Perren TJ, McElwain TJ. High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease. Br J Cancer. 1989 Apr;59(4):631-5. doi: 10.1038/bjc.1989.128. PMID: 2653400; PMCID: PMC2247129.
  7. Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood. 1993 Mar 1;81(5):1137-45. PMID: 8443375.
  8. Bierman PJ, Bagin RG, Jagannath S, Vose JM, Spitzer G, Kessinger A, Dicke KA, Armitage JO. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients. Ann Oncol. 1993 Nov;4(9):767-73. doi: 10.1093/oxfordjournals.annonc.a058662. PMID: 8280658.
  9. Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A, Arora M, Ramsay NK, Orchard PJ, MacMillan ML, Burns LJ. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006 Oct;12(10):1065-72. doi: 10.1016/j.bbmt.2006.06.006. PMID: 17084370.
  10. Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A, Oates J, Wotherspoon A, Horwich A. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma. Ann Oncol. 2008 Jul;19(7):1312-1319. doi: 10.1093/annonc/mdn052. Epub 2008 Mar 19. PMID: 18356139.
  11. Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL, Gascoyne RD, Hogge DE, Nantel SH, Shepherd JD, Smith CA, Song KW, Sutherland HJ, Toze CL, Voss NJ, Nevill TJ. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood. 2005 Aug 15;106(4):1473-8. doi: 10.1182/blood-2004-12-4689. Epub 2005 May 3. PMID: 15870180.
  12. Herrera AF, Chen RW, Palmer J, Tsai N, Mei M, Popplewell LL, Nademanee AP, Nikolaenko U, McBride K, Ortega R, Song JY, Rosen S, Kwak LW, Forman SJ, Lee HJ. PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma. Blood. 2019;134(Suppl_1):239.
  13. Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston PB, Mei M, Popplewell L, Armenian SH, Cao T, Farol L, Sahebi F, Spielberg R, Chen R, Nademanee AP, Peters L, Kennedy N, Rosen ST, Kwak LW, Forman SJ, Feldman TA. Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma. Blood. 2020;136(Suppl_1):19.
  14. Bachier C, Schade H, Zoghi B, Ramakrishnan A, Shah NN. A phase II Single Arm Study of Nivolumab As Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Hodgkin Lymphoma at Risk of Relapse or Progression. Blood. 2021;138(Suppl_1):624.
  15. Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease. Ann Oncol. 2003;14 Suppl 1:i11-6. doi: 10.1093/annonc/mdg703. PMID: 12736225.
  16. Voorhees TJ, Beaven AW. Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma. Cancers (Basel). 2020 Oct 8;12(10):2887. doi: 10.3390/cancers12102887. PMID: 33050054; PMCID: PMC7601361.
  17. Zinzani PL, Pellegrini C, Cantonetti M, Re A, Pinto A, Pavone V, Rigacci L, Celli M, Broccoli A, Argnani L, Pulsoni A. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients. Oncologist. 2015 Dec;20(12):1413-6. doi: 10.1634/theoncologist.2015-0227. Epub 2015 Oct 23. PMID: 26500229; PMCID: PMC4679088.
  18. Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz S, Kobos R, Kumar A, Matasar M, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Shukla N, Steinherz P, Straus D, Trippett T, Younes A, Zelenetz A, Moskowitz CH. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015 Mar;16(3):284-92. doi: 10.1016/S1470-2045(15)70013-6. Epub 2015 Feb 13. PMID: 25683846.
  19. Schimmoeller CJ, Bastian C, Fleming J, Morales J. A Review of Hodgkin Lymphoma in the Era of Checkpoint Inhibitors. Cureus. 2023 Jul 10;15(7):e41660. doi: 10.7759/cureus.41660. PMID: 37565112; PMCID: PMC10411984.
  20. Pangarsa EA, Naibaho RM, Yunarvika V, Setiawan B, Santosa D, Suharti C. The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin's Lymphoma. Case Rep Hematol. 2021 Nov 3;2021:9632427. doi: 10.1155/2021/9632427. PMID: 34777885; PMCID: PMC8580659.
  21. Colita A, Colita A, Bumbea H, Croitoru A, Orban C, Lipan LE, Craciun OG, Soare D, Ghimici C, Manolache R, Gelatu I, Vladareanu AM, Pasca S, Teodorescu P, Dima D, Lupu A, Coriu D, Tomuleasa C, Tanase A. LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation. Front Oncol. 2019 Sep 10;9:892. doi: 10.3389/fonc.2019.00892. PMID: 31552193; PMCID: PMC6746965.
  22. Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, García-Conde J, Jarque I, Caballero MD, Ferrà C, López A, García-Laraña J, Cabrera R, Carrera D, Ruiz-Romero MD, León A, Rifón J, Díaz-Mediavilla J, Mataix R, Morey M, Moraleda JM, Altés A, López-Guillermo A, de la Serna J, Fernández-Rañada JM, Sierra J, Conde E; Grupo Español de Linformas/Transplante Autólogo de Médula Osea Spanish Cooperative Group. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Español de Linfomas/Transplante Autólogo de Médula Osea Spanish Cooperative Group. J Clin Oncol. 2001 Mar 1;19(5):1395-404. doi: 10.1200/JCO.2001.19.5.1395. PMID: 11230484.

Figures:

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?